A clinical development paradigm for cancer vaccines and related biologics. - Wikidata - awgldk - TriplyDB

A clinical development paradigm for cancer vaccines and related biologics.

A clinical development paradigm for cancer vaccines and related biologics.

http://www.wikidata.org/entity/Q34596591

about

Improved endpoints for cancer immunotherapy trials Progress in immunotherapy for non-small cell lung cancer Future directions for the early detection of recurrent breast cancer Imaging Biomarkers in Immunotherapy Immunotherapy response assessment in neuro-oncology: a report of the RANO working group Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.An integrative paradigm to impart quality to correlative science.Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.Designing therapeutic cancer vaccine trials with delayed treatment effect.The strong financial case for regenerative medicine and the regen industry.Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis Strategies to use immune modulators in therapeutic vaccines against cancer The immuno-oncology framework: Enabling a new era of cancer therapy.Releasing the brake on the immune system: ipilimumab in melanoma and other tumors Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.Therapeutic cancer vaccines: are we there yet?Control of advanced cancer: the road to chronicity.Vitespen: a preclinical and clinical review.Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.Anti-idiotypic nanobody as citrinin mimotope from a naive alpaca heavy chain single domain antibody library.Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine.BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.Cancer vaccines: what do we need to measure in clinical trials?Defining the critical hurdles in cancer immunotherapy.Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?Role of vaccine therapy in cancer: biology and practice Toward the harmonization of immune monitoring in clinical trials: quo vadis?Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.Overview of cancer vaccines: considerations for development.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Cancer vaccines: moving beyond current paradigms.Vaccine immunotherapy in breast cancer treatment: promising, but still early.

P2860

Q24603112-8BC57925-FAE5-4757-A7DD-CFD561FA7EDA Q26865725-CE0B02A5-1885-4787-AB6E-822AA8CFCF8D Q27022040-0C3A961D-EB32-419B-A640-026CE3F4858B Q28079871-B032DECD-C101-4DEB-AAF0-D638CDF7FC19 Q28083009-CBD76C16-A811-4F83-8F66-2B1E8857B686 Q28744503-EC50F2E6-6CAD-4EF0-B2F2-C9003AD53110 Q30370848-66E4CB57-2EE5-45F9-94F3-E9EC1E4B36FF Q30439109-0DFC5F4F-2875-4FDE-8E22-3D55C2F5F341 Q30444086-F074162B-3201-4834-86A5-78AFE810C0A3 Q33619141-333553A2-367E-4533-9C0C-354443EE14B2 Q33619191-10D77920-8F5C-484B-8E56-03B89FFBF1FB Q33765942-167E37DC-A866-419B-B588-2FB22177E7F6 Q33886261-95E247BB-B6BF-4099-B853-41093C012241 Q33908263-56AA191D-406A-4E15-80D9-89F56EE84E9D Q34011549-036C4629-7B6C-497B-A18D-1B46CD1C8B30 Q34170003-DE08E580-CBF3-4B9D-B92F-C353647B7BAC Q34275601-742E7159-19B9-4A95-9C40-12244BCE43FF Q34284462-3D88E5FA-EFAB-48D4-A542-0F87559905BF Q34447732-355FC348-6D7A-4EF6-84AF-8208E2062E9C Q34480536-2CAA95E8-B062-4E97-BD74-3BA8C7CC3EE9 Q34635795-BEBBB093-AA5D-4AD7-9C84-1AFC59E2E959 Q34786691-E28F27AE-8762-4D90-9C08-EFA3DBE89D13 Q34874471-10119900-8437-47F4-A3D9-E6AE8FB8AF64 Q34996187-2FAB22EC-3BBB-49E4-BC30-3EBB12F97124 Q35065923-42B8C26D-977D-4CCA-959A-A843AB99613E Q35175762-614DA952-BCE6-431E-9A25-3351B49A1EF8 Q35614217-359E6F57-3CF6-4332-855F-2554A17555A8 Q35774908-0C83E4AE-3D81-4A5D-8618-CA9A2556FF07 Q35828614-952DC0A0-19F2-42AA-BAFF-6A91A9BB0D73 Q35836409-457D01C9-86FF-42B6-96E3-9DEC57C8BB3A Q35886597-E31459A2-4F70-4E96-80F1-CE252CEA366C Q35916968-C71DF1D3-5951-420E-8B65-845CA4C8C5AA Q36095223-278681E9-0E4D-4BAB-A249-F2F262BB7EF0 Q36256420-6656803F-A7F9-4C7F-AC8D-716FEC6AF027 Q36293565-22CD6D0C-629E-44FC-8E73-6567CBABBD0F Q36352693-4A7CA35B-26CF-4A46-AB25-3324B453A6C6 Q36631339-BEDBF736-8B0A-494C-901D-3A9A2E3EE6BD Q36708792-61830386-146D-445F-845B-9E570DE268F3 Q36868126-49DC399E-93B7-47DB-ABF5-E15EA377C80A Q36950477-90706B7B-6B7E-4689-BAFD-51A664C97FCC

P2860

A clinical development paradigm for cancer vaccines and related biologics.

http://www.wikidata.org/entity/Q34596591

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

A clinical development paradigm for cancer vaccines and related biologics.

@ast

A clinical development paradigm for cancer vaccines and related biologics.

@en

A clinical development paradigm for cancer vaccines and related biologics.

@nl

type

label

A clinical development paradigm for cancer vaccines and related biologics.

@ast

A clinical development paradigm for cancer vaccines and related biologics.

@en

A clinical development paradigm for cancer vaccines and related biologics.

@nl

prefLabel

A clinical development paradigm for cancer vaccines and related biologics.

@ast

A clinical development paradigm for cancer vaccines and related biologics.

@en

A clinical development paradigm for cancer vaccines and related biologics.

@nl

P1433

Q34596591-6B9EB0AB-6713-4EA6-8930-C3134601D71A

P1476

Q34596591-39B99BE2-ED9B-4954-8A6C-C8D856F01175

P2093

Q34596591-75EFA4DE-1542-4DF5-A48A-8D79F4FBB5FF

Q34596591-A1C57470-6475-4233-8F09-34D1E700D437

Q34596591-A4E2C3F9-A500-4854-9F76-B6B380D032C5

Q34596591-A53E249C-1060-4A9C-B2E4-4AE95BC3F5AA

Q34596591-B4A78A34-4174-4CDE-B81F-161AC2B198D5

Q34596591-B9DBFF37-3C7B-40FF-AA28-7131BA0B5FC4

Q34596591-DAB74A33-C0A2-4BD4-A3E2-A6059BCCFFB6

Q34596591-E66A7BE8-18B7-4F03-BA66-C2E736842518

Q34596591-EBF70A10-19E1-4F34-BEB2-42403CD5590E

Q34596591-F2B8C04F-013D-49C9-B16C-A58FAF1BA95E

P304

Q34596591-4832C0F6-BC62-4D8E-9C8D-10947D3194B1

P31

Q34596591-08AEEE05-1E22-47C3-811A-1AFB5CE4C367

P356

Q34596591-6211C13E-316B-433F-9D57-43F1C1D111EC

P433

Q34596591-D3083BE9-311D-4511-9D11-B187B21D5CAD

P478

Q34596591-9BCC4EA1-CF75-4565-8E33-7B896FBA3A38

P50

Q34596591-A4C0528A-0FA5-4FF2-B110-76FB55BC9932

Q34596591-A78E59C0-C087-44A2-A313-CB105ECA705D

P577

Q34596591-B55BDC0D-28C7-4B3D-8E07-0B15BA197E0B

P698

Q34596591-7BBEBD04-7C31-4055-BFF2-88C07F9A7E7F

P356

01.CJI.0000211341.88835.AE

P1433

Journal of Immunotherapy

P1476

A clinical development paradigm for cancer vaccines and related biologics.

@en

P2093

Axel Hoos

http://www.w3.org/2001/XMLSchema#string

Brent Blumenstein

http://www.w3.org/2001/XMLSchema#string

Cancer Vaccine Clinical Trial Working Group

http://www.w3.org/2001/XMLSchema#string

Geoffrey Nichol

http://www.w3.org/2001/XMLSchema#string

Giorgio Parmiani

http://www.w3.org/2001/XMLSchema#string

Hans Loibner

http://www.w3.org/2001/XMLSchema#string

Kristen Hege

http://www.w3.org/2001/XMLSchema#string

Natalie Sacks

http://www.w3.org/2001/XMLSchema#string

Ulrich Keilholz

http://www.w3.org/2001/XMLSchema#string

Walter Urba

http://www.w3.org/2001/XMLSchema#string

P304

1-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.CJI.0000211341.88835.AE

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Eggermont

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17198079

http://www.w3.org/2001/XMLSchema#string